NO20010964L - Alkynyl-substituerte quinolin-2-onderivater nyttige som anticancer midler - Google Patents

Alkynyl-substituerte quinolin-2-onderivater nyttige som anticancer midler

Info

Publication number
NO20010964L
NO20010964L NO20010964A NO20010964A NO20010964L NO 20010964 L NO20010964 L NO 20010964L NO 20010964 A NO20010964 A NO 20010964A NO 20010964 A NO20010964 A NO 20010964A NO 20010964 L NO20010964 L NO 20010964L
Authority
NO
Norway
Prior art keywords
alkynyl
anticancer agents
derivatives useful
substituted quinoline
quinoline
Prior art date
Application number
NO20010964A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010964D0 (no
Inventor
Susan Deborah La Greca
Joseph Peter Lyssikatos
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20010964D0 publication Critical patent/NO20010964D0/no
Publication of NO20010964L publication Critical patent/NO20010964L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20010964A 1998-08-27 2001-02-26 Alkynyl-substituerte quinolin-2-onderivater nyttige som anticancer midler NO20010964L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9814598P 1998-08-27 1998-08-27
PCT/IB1999/001398 WO2000012499A1 (en) 1998-08-27 1999-08-06 Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents

Publications (2)

Publication Number Publication Date
NO20010964D0 NO20010964D0 (no) 2001-02-26
NO20010964L true NO20010964L (no) 2001-04-26

Family

ID=22267481

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010964A NO20010964L (no) 1998-08-27 2001-02-26 Alkynyl-substituerte quinolin-2-onderivater nyttige som anticancer midler

Country Status (40)

Country Link
US (3) US6150377A (de)
EP (1) EP1107963B1 (de)
JP (1) JP3495706B2 (de)
KR (1) KR20010072991A (de)
CN (1) CN1314904A (de)
AP (1) AP2001002079A0 (de)
AT (1) ATE321037T1 (de)
AU (1) AU4925499A (de)
BG (1) BG105365A (de)
BR (1) BRPI9913138B8 (de)
CA (2) CA2578326C (de)
CO (1) CO5130017A1 (de)
CZ (1) CZ2001660A3 (de)
DE (1) DE69930518T2 (de)
DZ (1) DZ2880A1 (de)
EA (1) EA200100135A1 (de)
EE (1) EE200100118A (de)
ES (1) ES2259237T3 (de)
GE (1) GEP20033001B (de)
GT (1) GT199900140A (de)
HK (1) HK1039123A1 (de)
HR (1) HRP20010142A2 (de)
HU (1) HUP0103228A3 (de)
ID (1) ID27562A (de)
IL (1) IL141239A0 (de)
IS (1) IS5818A (de)
MA (1) MA26680A1 (de)
NO (1) NO20010964L (de)
NZ (1) NZ509372A (de)
OA (1) OA11645A (de)
PA (1) PA8480101A1 (de)
PE (1) PE20000986A1 (de)
PL (1) PL346426A1 (de)
SK (1) SK2442001A3 (de)
SV (1) SV1999000141A (de)
TN (1) TNSN99162A1 (de)
TR (1) TR200101343T2 (de)
UY (1) UY25682A1 (de)
WO (1) WO2000012499A1 (de)
ZA (1) ZA200101173B (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114503A1 (en) * 1997-06-16 2003-06-19 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
HRP20000904A2 (en) * 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
ATE289602T1 (de) * 1998-08-27 2005-03-15 Pfizer Prod Inc Quinolin-2-on-derivate verwendbar als antikrebsmittel
TR200101343T2 (tr) * 1998-08-27 2001-09-21 Pfizer Products Inc. Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
KR20010102073A (ko) 1999-02-11 2001-11-15 실버스타인 아써 에이. 항암제로 유용한 헤테로아릴-치환된 퀴놀린-2-온 유도체
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US6838467B2 (en) 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
ATE321038T1 (de) 2000-09-25 2006-04-15 Janssen Pharmaceutica Nv Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
JP4974439B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
WO2002024686A2 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7173040B2 (en) 2000-09-25 2007-02-06 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
DE60139080D1 (de) 2000-11-21 2009-08-06 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
AU2002218436A1 (en) * 2000-12-19 2002-07-01 Pfizer Products Inc. Crystal forms of 6-((4-chloro-phenyl) -hydroxy-(-3-methyl- 3h-imidaol-4-yl) -methyl) -4-(3-ethynyl-phenyl) -1-methyl-1h- quinolin-2-one, 2,3- dihydroxybutanedioate salts and method of production
WO2002051835A1 (en) * 2000-12-27 2002-07-04 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
EA006770B1 (ru) * 2001-03-12 2006-04-28 Янссен Фармацевтика Н.В. Способ получения соединений имидазола
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
US20050165053A1 (en) * 2001-06-04 2005-07-28 Cytovia, Inc. Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1408971A4 (de) 2001-06-21 2006-01-25 Ariad Pharma Inc Neue chinoline und ihre verwendungszwecke
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
EP1458720B1 (de) 2001-12-19 2009-03-18 Janssen Pharmaceutica N.V. Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren
ATE364384T1 (de) 2002-03-22 2007-07-15 Janssen Pharmaceutica Nv Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
JP3814285B2 (ja) * 2002-12-19 2006-08-23 ファイザー・インク 眼疾患の治療に有用なプロテインキナーゼ阻害剤としての２−（１ｈ−インダゾール−６−イルアミノ）−ベンズアミド化合物
JP4691041B2 (ja) 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
ATE492544T1 (de) * 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
GEP20104906B (en) 2004-08-26 2010-02-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
WO2006021886A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
EP1815247B1 (de) 2004-11-05 2013-02-20 Janssen Pharmaceutica NV Therapeutische verwendung von farnesyltransferase-hemmern und verfahren zur überwachung der wirksamkeit
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
AU2006275528B2 (en) 2005-07-29 2012-03-08 Children's Hospital Medical Center GTPase inhibitors and methods of use and crystal structure of Rac-1 GTPase
KR101536506B1 (ko) * 2005-09-07 2015-07-14 암젠 프레몬트 인코포레이티드 액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
CA2623125A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP1968591A4 (de) 2005-12-23 2010-02-17 Link Medicine Corp Behandlung von synucleinopathien
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
MX2008013533A (es) 2006-04-20 2009-01-15 Janssen Pharmaceutica Nv Compuestos heterociclicos como inhibidores de c-fms cinasa.
EP2016070B1 (de) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitoren von c-fms-kinase
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
ES2392630T3 (es) 2006-08-21 2012-12-12 F. Hoffmann-La Roche Ag Terapia antitumoral con anticuerpos anti-VEGF
EP2155197A4 (de) * 2007-03-09 2011-10-12 Link Medicine Corp Behandlung von lysosomalen speicherkrankheiten
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
MX2011005096A (es) 2008-11-13 2011-11-18 Link Medicine Corp Derivados de azaquinolinona y usos de los mismos.
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2542893A2 (de) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
CN104870454B (zh) 2012-08-07 2020-03-03 詹森药业有限公司 用于制备杂环酯衍生物的方法
CN107266405A (zh) 2012-08-07 2017-10-20 詹森药业有限公司 用于制备c‑fms激酶抑制剂的方法
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
EA201890512A1 (ru) 2015-08-17 2018-09-28 Кура Онколоджи, Инк. Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
MX2018006781A (es) 2015-12-03 2018-11-09 Agios Pharmaceuticals Inc Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
RS61745B1 (sr) 2016-11-03 2021-05-31 Kura Oncology Inc Inhibitori farneziltransferaze za upotrebu u tretiranju kancera
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
KR102003179B1 (ko) 2017-02-21 2019-07-23 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2020001207A (es) 2017-08-07 2020-03-20 Kura Oncology Inc Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
EP3873469A2 (de) 2018-11-01 2021-09-08 Kura Oncology, Inc. Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren
US20220071941A1 (en) 2018-12-21 2022-03-10 Kura Oncology, Inc. Therapies for squamous cell carcinomas
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
SG11202110472WA (en) 2019-03-29 2021-10-28 Kura Oncology Inc Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
EP4013402B1 (de) 2019-08-16 2024-11-06 Children's Hospital Medical Center Cdc-42-inhibitoren zur verwendung bei der behandlung von altersverbundener depression, sarkopenie oder gebrechlichkeit
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
CN119968374A (zh) * 2022-09-22 2025-05-09 南开大学 三尖杉酯碱类衍生物及其药物组合物、制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EE03484B1 (et) * 1995-12-08 2001-08-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
TR200101343T2 (tr) * 1998-08-27 2001-09-21 Pfizer Products Inc. Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri

Also Published As

Publication number Publication date
US6294552B1 (en) 2001-09-25
BG105365A (en) 2001-11-30
US6579887B2 (en) 2003-06-17
EE200100118A (et) 2002-06-17
DZ2880A1 (fr) 2003-12-15
NO20010964D0 (no) 2001-02-26
CN1314904A (zh) 2001-09-26
DE69930518D1 (de) 2006-05-11
HUP0103228A2 (hu) 2002-02-28
UY25682A1 (es) 2000-03-31
CO5130017A1 (es) 2002-02-27
HRP20010142A2 (en) 2002-02-28
EP1107963A1 (de) 2001-06-20
ES2259237T3 (es) 2006-09-16
HK1039123A1 (zh) 2002-04-12
DE69930518T2 (de) 2006-09-21
AU4925499A (en) 2000-03-21
TR200101343T2 (tr) 2001-09-21
GEP20033001B (en) 2003-06-25
CA2341690A1 (en) 2000-03-09
PA8480101A1 (es) 2003-06-30
ZA200101173B (en) 2002-04-12
NZ509372A (en) 2003-08-29
SK2442001A3 (en) 2002-10-08
AP2001002079A0 (en) 2001-03-31
BR9913138A (pt) 2001-05-08
CA2341690C (en) 2007-04-17
US6150377A (en) 2000-11-21
CA2578326A1 (en) 2000-03-09
SV1999000141A (es) 2000-07-06
ATE321037T1 (de) 2006-04-15
GT199900140A (es) 2001-02-14
PE20000986A1 (es) 2000-09-30
BR9913138B1 (pt) 2013-11-05
JP3495706B2 (ja) 2004-02-09
IS5818A (is) 2001-01-19
CA2578326C (en) 2009-11-24
WO2000012499A1 (en) 2000-03-09
CZ2001660A3 (cs) 2002-05-15
IL141239A0 (en) 2002-03-10
BRPI9913138B8 (pt) 2016-05-17
OA11645A (en) 2004-11-16
EP1107963B1 (de) 2006-03-22
MA26680A1 (fr) 2004-12-20
KR20010072991A (ko) 2001-07-31
JP2002523504A (ja) 2002-07-30
ID27562A (id) 2001-04-12
PL346426A1 (en) 2002-02-11
TNSN99162A1 (fr) 2005-11-10
US20020128287A1 (en) 2002-09-12
EA200100135A1 (ru) 2001-08-27
HUP0103228A3 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
NO20010964D0 (no) Alkynyl-substituerte quinolin-2-onderivater nyttige som anticancer midler
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
NO2019016I1 (no) dasatinib
NO20026195D0 (no) Substituerte-triazolopyrimidiner som anticancer midler
NO20015477L (no) 4,5,6,7-tetrahydroindazolderivater som antitumormidler
NO20014412L (no) Forbindelser nyttige som anti-inflammatoriske midler
DK1930330T3 (da) Pleuromutilinderivater som antimikrobielle midler
NO20011738L (no) Heterocyclylaminometyloksazolidinoner som antibakterielle midler
NO2011017I1 (no) Retigabin i hvilken som helst form som er beskyttet av basis patentet
NO20013909D0 (no) Heteroaryl-substituerte kinolin-2-on derivater nyttige som anticancer midler
NO20002162L (no) Tienopyrimidin- og tienopyridinderivater nyttige som anticancer midler
NO20032531D0 (no) Tetralon-derivater som antitumormidler
NO20022888L (no) Lipopeptider som antibakterielle midler
AR023440A1 (es) Composiciones antitranspirantes
DE50010505D1 (de) Gurtaufrollersystem
NO20022887L (no) Lipopeptider som antibakterielle midler
ID29785A (id) Komposisi-komposisi sampo
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
ATE257691T1 (de) Schweisshemmende zusammensetzungen
DE50012089D1 (de) Saugstrahlpumpe
NO20012965D0 (no) Sulfonyloksazolaminer som terapeutisk aktive forbindelser
NO20020457D0 (no) Benzenaminderivater som antikoagulanter
DK1075471T3 (da) Idolylderivater som serotonerge midler
ATE269253T1 (de) Teilbare mehrfachpackung
NO20000434D0 (no) Lyksofuranosyl benzimidazoler som antivirale midler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application